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Background. Radiofrequency ablation (RFA) has been recently advocated as an effective technique for the treatment of symptomatic
benign thyroid nodules. It is not known to what extent it may affect any subsequent thyroid surgery and/or histological diagnosis.
Materials and Methods. RFA was performed on 64 symptomatic Thy2 nodules (benign nodules) and 6 symptomatic Thy3 nodules
(follicular lesions/follicular neoplasms). Two Thy3 nodules regrew after the procedure, and these patients accepted to undergo
a total thyroidectomy. Here we present how RFA has affected the operation and the final pathological features of the surgically
removed nodules. Results and Conclusions. RFA is effective for the treatment of Thy2 nodules, but it should not be recommended
as first-line therapy for the treatment of Thy3 nodules (irrespective of their mutational status), as it delays surgery in case of
malignancy. Moreover, it is unknown whether RFA might promote residual tumor progression or neoplastic progression of Thy3
lesions. Nevertheless, here we show for the first time that one session of RFA does not affect subsequent thyroid surgery and/or
histological diagnosis.
1. Introduction
Thyroid nodules are an extremely common occurrence [1].
Until recently international guidelines suggested either no
treatment or surgery for patients with benign solid thyroid
nodules, depending on their size, cytology, and symptoms
[2]. In recent years, however, several nonsurgical minimally
invasive approaches for treating thyroid nodules have been
developed [3] and nowadays they represent an acceptable
alternative to surgery for treating symptomatic benign thy-
roid nodules [3]. These techniques include percutaneous
ethanol injection therapy (PEIT), laser ablation therapy
(LAT), and radiofrequency ablation (RFA).
Among these techniques RFA is not only an effective [4]
but also a reasonably safe [5] treatment option for recurrent
cysts [6], mixed or solid benign thyroid nodules causing
cosmetic concerns, local pain, or hyperthyroidism [7, 8].
Nevertheless, RFA is relatively new, so some issues regarding
its outcomes still exist. For example, one of the questions that
remains unanswered is what would happen if a thyroid cancer
were not detected before starting RFA and was left untreated?
Would RFA jeopardize a subsequent operation and/or hinder
histological diagnosis?
Herewe present the 2-year follow-up results of 70 patients
who underwent RFA. In particular, 64 patients had Thy2
nodules (benign nodules) and 6 patients had Thy3 nodules
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(follicular lesions/follicular neoplasms). Because of nodule
regrowth, two of these patients subsequently underwent
surgery after being treatedwithRFA. Based on our experience
the aim of this report is to describe the surgical and patholog-
ical changes after RFA of thyroid nodules and to comment on
the use of RFA for Thy3 nodules.
2. Materials and Methods
2.1. Study Population. This is a retrospective study of the
2-year follow-up results of 64 patients with Thy2 thyroid
nodules and 6 patients with Thy3 nodules who underwent
RFA. Before the procedure, nodules were evaluated by
fine needle aspiration biopsy (FNAB) twice and classified
according to the British and Italian reporting systems for
thyroid cytopathology [9, 10], where Thy2 corresponds to
Bethesda Category II (benign nodules), and Thy3 corre-
sponds to Bethesda Categories III and IV nodules (follicular
lesions/follicular neoplasms) [11]. A single session of RFA
was performed on 64 Thy2 solitary nodules, according to
current recommendations [12]. A single session of RFA was
also performed on 6 symptomatic Thy3 nodules in surgically
high-risk individuals or patients refusing surgery. These
patients did not have a family history of thyroid cancer
and did not present suspicious lymph nodes. Their nodules
were single, unchanged over the last three years, with no
calcifications, no evidence of nuclear atypia [13, 14], and
without BRAF or NRAS mutations. Patients were prepared
for the procedure according to current recommendations [12]
and before it they all signed an informed consent form after
full explanation of the purpose and nature of all procedures
used. Secondly, informed consent to use their clinical data for
scientific purposes was obtained from each patient, according
to the guidelines of the Azienda Ospedaliero-Universitaria di
Trieste.
2.2. Radiofrequency Ablation Technique and Follow-Up. RFA
was performed in an outpatient regimen by a well-trained
radiologist experienced in US, FNAB, and RFA procedures.
Before ablation, an intravenous access was obtained via an
antecubital vein. Patients were placed in a supine position
with their neck extended. They underwent local anesthesia
at the puncture site with 2% lidocaine hydrochloride. The
procedure required conscious sedation following an intra-
venous injection of 2-3mg of midazolam.We used a 450 kHz
radiofrequency generator (AMICA-GENmodel AGN-H-1.0,
HS Hospital Service SpA, Italy) delivering up to 200W on a
50Ω load and 18-gauge, internally cooled, monopolar elec-
trodes (RFAMICA-PROBEmodel RFH18100V1,HSHospital
Service SpA, Italy) featuring a shaft length of 10 cm and an
exposed tip length of either 7, 10, or 15mm. The exposed tip
length selectionwas based on the nodule volume: 7mmactive
tips were used for the treatment of smaller nodules (<10mL),
10mm active tips in intermediate size nodules (10–20mL),
and 15mm active tips in larger nodules (>20mL).
The electrode was inserted into the thyroid nodule with
a transisthmic approach under US-guidance by using a 5–
18MHz linear probe on a real-time US system (Aplio XG,
Toshiba Corp. Medical Systems). To perform RFA the
moving-shot technique was used [15]. The initial RF power
settings ranged between 30W and 50W depending on the
electrode exposed tip length: the shorter the active tip,
the lower the power. The ablation procedure always started
from the deepest areas of the nodule. If a hyperechoic zone
had not formed at the electrode tip within 30 seconds, the
RF generator output was progressively increased in 10W
steps, up to a maximum power ranging between 60W and
80W (once again depending on the active tip length). Then,
once the treated zone had become hyperechoic and the
electric impedance measured by the generator increased, the
electrode was moved towards another area of the nodule.
Ablation was terminated when transient hyperechoic zones
could be identified around the entire nodule. At the end of the
procedure, patients remained under observation for a couple
of hours.
To evaluate RFA results, patients underwent an ultra-
sonography (US) and TSH measurement at baseline, 1, 3, 6,
12, and 24 months after the procedure. To simplify the cal-
culation of the nodule volumes prior to RFA (𝑉pre) and after
RFA (𝑉post) out of cross-sectional measurements taken from
the respective US images, each nodule was approximated to
an ellipsoid, both before RFA (with diameters 𝐴pre as major
axis, 𝐵pre and 𝐶pre as minor axis, both perpendicular to𝐴pre)
and after RFA (with diameters 𝐴post, 𝐵post, and 𝐶post, named
after their pre-RFA counterparts). Therefore, the following
formulas were used: 𝑉pre = 𝜋 ∗ 𝐴pre ∗ 𝐵pre ∗ 𝐶pre/6;
𝑉post = 𝜋 ∗ 𝐴post ∗ 𝐵post ∗ 𝐶post/6. The percentile volume
reduction induced by the RFA treatment was calculated as
Δ𝑉 = 100∗ (𝑉pre −𝑉post)/𝑉pre. Technical success was deemed
to be achievedwhen a volume reductionΔ𝑉 greater than 50%
at 6 months from the procedure [4] was observed.
2.3. Surgery. Two patients were operated on after RFA. The
operations were carried out by the same surgical team. The
intraoperative nerve integrity monitoring (NIM) system was
used in order to check the laryngeal nerve functionality.
Patients, under general anaesthesia, were placed in the supine
position with the neck extended. Thyroidectomy was per-
formed by a cervicotomy of 2–5 cm in the middle area of the
neck, approximately 2 cm above the sternal notch. Minimal
subplatysmal flaps were created.Themidline was incised and
the strap muscles were retracted laterally. The vessels of the
upper thyroid peduncle were selectively ligated or closed by
conventional vascular clips. Special carewas taken to preserve
the parathyroid glands and the inferior laryngeal nerves.
Once the thyroid had been removed, the area was examined
for bleeding. If there was no bleeding, the incision was closed
with sutures. In both cases, a surgical drain was placed to
remove fluids from the area in the following days.Anaesthesia
was discontinued and medication was given to wake the
patient. Both patients had laryngoscopic examination for
vocal cord mobility before and one month after surgery.
Serum calcium levels were measured on the first and second
day after surgery and weekly for the first month. Parathyroid
hormone was measured 3 months after thyroid surgery.
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Table 1
Characteristics Thy2 (𝑛 = 64) Thy3 (𝑛 = 6) 𝑝 value
Age (years) 60.47 ± 1.89 61.16 ± 5.62 n.s.
Sex (M) 17 3 n.s.
Nodule max diameter (mm) 36.04 ± 2.40 38.17 ± 4.12 n.s.
Nodule volume (mL) 13.81 ± 1.86 17.46 ± 5.57 n.s
Solidity > 50% 55 6 n.s
Solidity < 50% 9 0 n.s.
BRAF mutations Not tested Absent —
NRAS mutations Not tested Absent —
TSH (𝜇U/mL) 1.35 ± 0.23 1.41 ± 0.47 n.s.
Calcitonin (pg/mL) 1.62 ± 0.14 1.42 ± 0.36 n.s.
Table 2
Characteristics Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Age (years) 71 60 50 53 79 42
Sex M F F F M M
Nodule max diameter (mm) 53 42 41 38 32 23
Nodule volume (mL) 40 24 19 11 7 2
Type of nodule Solid nodule Solid nodule Solid nodule Solid nodule Solid nodule Solid nodule
FNAB Thy3 Thy3 Thy3 Thy3 Thy3 Thy3
BRAF mutations Absent Absent Absent Absent Absent Absent
NRAS mutations Absent Absent Absent Absent Absent Absent
TSH (𝜇U/mL) 1.38 1.94 1.22 0.65 0.02 3.35
Calcitonin (pg/mL) 1.3 1 1 1 1 3.2
Anti-TPO and/or Anti-TG Abs Absent Absent Absent Absent Absent Absent
2.4. Pathology. After surgery, four pathologists examined the
thyroid sections stained with hematoxylin and eosin. In one
case HBME-1 staining, which is considered a good marker of
malignancy [16, 17], was also performed and evaluated.
Although molecular biology analyses had already been
performed on the FNA of all Thy3 nodules before RFA,
they were repeated on the surgically resected nodules. BRAF
mutational status (including V600E/Ec, V600D, 600K, and
V600R mutations) was evaluated byTherascreen BRAF RSQ
PCR kit (Qiagen, UK). NRAS mutations were analysed by
NRAS Pyrokit for mutations in codons 12, 13, 56, 61, 117, and
146 (Qiagen, UK). DNA was extracted from paraffin blocks
and tested by using real-time polymerase chain reaction on
the Rotor-Gene Q MDx 5plex HRM instrument (Qiagen,
UK) and on the PyroMark Q24 System (Qiagen, UK),
respectively.
2.5. Statistical Analysis. Continuous variables were evaluated
by ANOVA.The 𝜒2 test was used to compare sex and nodule
solidity between the two groups. The criterion for statistical
significance was 𝑝 < 0.05. All analyses were conducted with
SAS (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. 2-Year Follow-Up Results after RFA. Thecharacteristics of
both groups of nodules (Thy2 andThy3) aswell as the singular
characteristics of the 6 patients with Thy3 are reported in
Tables 1 and 2. One session of RFA significantly reduced
Thy2 nodule volume by 50%, 64%, 70%, 71%, and 67% after
1, 3, 6, 12, and 24 months from the procedure (Figure 1(a)).
Technical success was obtained in allThy2 nodules and it was
maintained up to 24months. On the other hand, even though
RFA significantly reducedThy3 nodule volume by onemonth
(Figure 1(a)), two of these nodules regrew. In particular, after
6 months from the procedure one nodule regrew by 73%
as compared to its smallest volume achieved (Figure 1(b);
Case 1), while the other, after 24 months from the procedure,
regrew by 57% as compared to its smallest volume achieved
(Figure 1(b); Case 2). This is the reason why the curve
representing Thy3 nodule volume reduction (Figure 1(a))
deviates markedly from what we observed for Thy2 nodules.
Nevertheless, in the remaining four Thy3 nodules treated
with RFA, the procedure significantly reduced their volume
as much as what was observed in Thy2 nodules (Figure 1(b))
and this was maintained throughout all the 2-year follow-
up period (Figure 1(b)). Given that nodule growth is a sign
for potential malignancy [18] and that this was observed in
two Thy3 nodules, where the rate of malignancy (including
microcarcinomas) is estimated to be between 14 and 48% [19],
the patients accepted to undergo thyroid surgery.
3.2. Case Presentation of Patients Who Underwent Surgery
after RFA. The first patient (Case 1) is a 71-year-old man who
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Figure 1: Volume (mL) reduction at 1, 3, 6, 12, and 24 months after RFA. (a) Dotted line represents Thy2 (𝑛 = 64) and continuous line
represents Thy3 (𝑛 = 6) nodule volume reduction; (b) the volume reduction of each Thy3 nodule is represented together with Thy2 (𝑛 = 64)
nodule volume reduction.
presented with a symptomatic thyroid nodule, which was a
follicular lesion (Thy3) with no evidence of nuclear atypia,
no BRAF, and no NRAS mutations. Given his unwillingness
to undergo surgery (in the past he had already undergone
several surgical operations) and his high surgical risk (he had
recently had a stroke), our multidisciplinary team [10] agreed
with the patient to treat his nodule with RFA. The second
patient (Case 2) is a 62-year-old woman who presented with
a symptomatic thyroid nodule, which was a follicular lesion
(Thy3) with no evidence of nuclear atypia, no BRAF, and no
NRAS mutations. Because of her unwillingness to undergo
surgery together with the stability of her nodule radiological
features at the follow-up visits for more than 3 years, we
agreed with the patient to treat her nodule by RFA. The
characteristics of these two patients are reported in Table 2
along with the characteristics of the other Thy3 nodules
treated with RFA. In the end, however, in both cases the
nodules regrew, which was a sign for potential malignancy,
and the patients agreed to undergo surgery.
3.3. Surgical Changes. In both cases, given the preoperative
diagnosis of follicular lesions Thy3, BRAF, and NRAS neg-
ative, we scheduled a total thyroidectomy. Patient vocal cord
mobility was normal before the procedure.Themean interval
between RFA and surgery was 15 months (range 6–24). The
midline incision and strap muscle retraction were feasible
and in both cases the operation began from the left side,
where the nodules were located, because it was the part most
at risk. Remarkably, we did not find any difficulty in the
ligation of the main vessels, nor in the recognition/isolation
of the laryngeal nerve and the parathyroid glands, which
could be always visualized. In particular, the consistency of
the thyroid parenchyma was not substantially affected by
RFA, and we did not see macroscopically burnt or scarred
tissue. Nor didwe see adhesionswith the surrounding tissues.
No problems were encountered in thyroid dissection. No
enlarged lymph nodes were found. Total thyroidectomy was
successfully completed in both cases. The mean operative
time was 98.5 ± 6.5 minutes and the postoperative hospital
stay was 2 days. After the operation, serum calcium levels
remained within the normal ranges in both patients. No
laryngeal nerve palsies or postoperative haematomas were
observed.
3.4. Pathological Changes. The final histopathological exam
showed that Case 1 was a minimally invasive follicular carci-
noma (Figure 2). In particular, in the excised thyroid gland
of Case 1 the left lobe was entirely occupied by a capsulated
nodule measuring 6.5 × 4.5 × 3.5 cm. The cut surface
showed a yellowish, heterogeneous nodule with a central
area of colliquative necrosis. Microscopically the tumor was
a microfollicular neoplasm with trabecular areas surrounded
by a thick capsule. Central scattered areas of hyaline sclerosis
and scarring, which were due to RFA, could also be seen
(Figure 2). However, these areas did not alter the capsule
and did not affect diagnostic assessment, since mushroom-
like capsular invasion could be clearly found in a few spots
(Figure 2).Therefore the final diagnosiswas that of a follicular
carcinoma (pT3Nx) and the patient received an ablative
dose of radioiodine, with no signs of recurrence at the post
thyroid ablation whole body scan. As for Case 2, this nodule
turned out to be a follicular neoplasm of undeterminate
malignant behaviour (Figure 3). In particular, in the excised
thyroid gland of Case 2, the left lobe was almost entirely
occupied by a capsulated lesion measuring 3.2 × 2.7 × 3 cm.
The cut surface showed a grayish white homogeneous mass.
Histopathological examination revealed that the nodule was
a microfollicular neoplasm with solid and trabecular areas,
surrounded by a thick capsule. Few signet ring cells, random
nuclear atypia, and clearing cell changes could be identified
(Figure 3). HBME-1 staining was negative. Central scattered
areas of hyaline sclerosis and scarring, which were due to
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Figure 2: Representative images of a follicular carcinoma previously treated with RFA. (a) The lower magnification (0.8x) picture shows
scattered areas of hyaline sclerosis and scarring due to RFA, which do not affect the capsule. (b-c) The higher magnification (4x and 10x,
resp.) pictures show spots of capsular invasion.
(a) (b)
Figure 3: Representative images of a follicular neoplasm of uncer-
tain malignant potential previously treated with RFA. (a) The lower
magnification (0.6x) picture shows central scattered areas of hyaline
sclerosis and scarring due to RFA, which do not affect the capsule.
(b) The higher magnification (40x) picture shows signet ring cells,
random nuclear atypia, and clearing cell changes.
RFA, could also be seen (Figure 3). Again, they did not alter
thyroid capsule. Since this neoplasm was well encapsulated
and an exhaustive search for evidence of capsular and vascu-
lar invasion provided only suspicious or doubtful rather than
definitive evidence, the final diagnosis was that of follicular
neoplasm of indeterminate malignant behaviour. Of note, in
both cases, BRAF and NRAS mutational status was analysed
postoperatively and, consistent with our previous results, we
did not find any mutations.
4. Discussion
Our study confirms the efficacy and applicability of current
guidelines, indicating that RFA can be used effectively to
treat benign thyroid nodules, cytologically defined as Thy2
nodules. In fact, RFA significantly reduced the volume of
all Thy2 nodules and this was maintained throughout the
study period [8]. This is consistent with previous studies
demonstrating that RFA can reduce nodule volume by 33–
58% after onemonth, by 51–85% after six months, and by 93%
after four years from the procedure [3].
On the other hand, our data demonstrates that RFA
should not be recommended as first-line therapy in Thy3
nodules, whose malignancy rate is between 14 and 48% [19].
This report shows that in 2 patients out of 6 (33%) with Thy3
nodules, which turned out to be cancers, RFA not only failed
to resolve the patients’ problem, but it also delayed surgery,
which is the recommended curative approach for thyroid
cancer [10]. While RFA is an effective and safe alternative to
repeat surgery in patients with locally recurrent small thyroid
cancers [20, 21], it is not yet recommended in patients with
thyroid cancer who have not had previous total thyroidec-
tomy and/or neck dissection [22]. Larger randomized studies
might demonstrate the long-term efficacy of RFA compared
to surgery for the first-line treatment of thyroid cancer.
Taking into account the rapid regrowth of the nodule
where we found a follicular carcinoma (Figure 1(b)), it should
be evaluated whether RFA might promote neoplastic cell
transformation or the progression of undetected thyroid
cancers. This is an important issue to address before rec-
ommending RFA for Thy3 nodules, since these nodules are
considered premalignant precursors of follicular carcinoma
[23], if they are not already a cytologically undetected thyroid
cancer [19]. A few reports have already raised the issue of
tumor regrowth in thyroid [24] as well as nonthyroid cancers
[25, 26]. As for thyroid cancer regrowth, Park and colleagues
found that 2 of the 9 recurrent thyroid cancers treated with
RFA regrew after a follow-up of at least 6 months from the
treatment [24]. Notably, in our cohort (as well as in the cohort
of Park) the nodules with a volume greater than 20mL were
those that regrew. So although the factors that might have
caused thyroid tumor regrowth remain unclear, it is possible
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that heat trauma as well as tumor size and behaviour might
have influenced nodule regrowth.
In hepatocellular carcinomas (HCC), for example, rapid
tumor progression and sarcomatous changes have been
reported after RFA [25, 26]. These events are believed to
be due to the progression of residual HCC, as it has been
demonstrated that insufficient RFA facilitates rapid progres-
sion of residual HCC [27], where suboptimal heat promotes
angiogenesis via hypoxia-inducible factor-1𝛼 and vascular
endothelial growth factor-A [28]. Moreover, it has also been
shown that even nontumor cells, such as tumor-associated
endothelial cells, which are exposed to RFA, change their
behaviour once exposed to insufficient RFA. In particular,
if these cells are not completely coagulated when exposed
to suboptimal (lower) temperatures, ranging from 42∘C to
47∘C, they exhibit enhanced angiogenesis and promote the
invasiveness of residual hepatocellular carcinomas [29]. In
addition to that, Breitenbuch et al. showed that RFA enhanced
the proliferation of distant, preexisting, undetected, resid-
ual single neoplastic cells, while destroying completely the
primary liver neoplasm [30]. This effect was attributed to
immunological and biological consequences of heat trauma
andwas consistentwith the report by Solbiati et al. that 57%of
patients treated with RFA developed new distant metastases
afterwards [31].
Nevertheless, our study also shows that in the remaining 4
patients (67%) withThy3 nodules, RFA significantly reduced
thyroid nodule volume and this was maintained up to 2
years, as in Thy2 nodules. Unfortunately, it is not possible
to determine if the Thy3 nodules that responded did not
regrow because they were benign or because they harboured
small neoplastic foci that have been entirely destroyed by
RFA, as happened in a group of microcarcinomas treated by
PLA [32]. It could be speculated that since the nodules that
responded to RFA were small lesions, we did not see any
regrowth there because they were entirely destroyed by the
procedure and no residual tissue was left. Therefore, before
recommending RFA for the treatment of Thy3 nodules, we
believe that further studies are needed: to exclude the risk that
this technique might significantly facilitate transformation of
follicular lesions into follicular carcinomas or promote the
progression of residual thyroid cancers, as well as to clarify
whether, on the other hand, it can be safely applied to Thy3
nodules regardless of/or depending on their size.
Having said that, we believe this study clearly demon-
strates that RFA does not affect subsequent thyroid surgery
and/or histological diagnosis. Based on our experience, the
surgical removal of thyroid nodules is not impacted by one
session of RFA, as the patients who had undergone this
procedure could be successfully operated on with no compli-
cations. In the thyroid, few data [33] exist on the operative
and pathological findings in patients having undergone
minimally invasive nonsurgical techniques. In the liver, on
the contrary, we know that RFA leads to the formation of a
fibrous capsule around an area of coagulative necrosis [34,
35]. For this reason we were concerned that RFA could have
induced fibrosis of the structures surrounding the nodule
and the thyroid, which actually did not happen. This could
be ascribed to our technique, since we are used to keeping
the active tip of the needle within the nodule all through
the procedure, which allows us to undertreat the areas
adjacent to the capsule and to the laryngeal nerve in order
to prevent possible complications, such as nerve injury. For
the same reason we believe the procedure did not affect the
histopathological examination of the thyroid. In the excised
thyroid glands, central and rather scattered areas of hyaline
sclerosis and scarring could be noted, which did not alter
the capsule and the tissue sufficiently to alter the diagnostic
assessment. In both cases the features of microfollicular
neoplasms could be identified and in one case we found some
spots of capsular invasion, leading us to the identification of
a follicular carcinoma.
In conclusion, RFA is effective for the treatment of Thy2
nodules, but in our experience it should not be recommended
for the treatment of Thy3 nodules (irrespective of their
mutational status), as it delays surgery in case of malignancy.
Moreover, further studies are needed to clarify whether RFA
might facilitate the transformation of follicular lesions to fol-
licular carcinomas and/or residual thyroid tumor progression
and thereforewhether it can be safely applied to the treatment
ofThy3 nodules. Nevertheless, here we show for the first time
that one session of RFA does not affect subsequent thyroid
surgery and histological diagnosis.
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